# Molecular Profiling of Advanced Soft-tissue Sarcomas

> **NCT03784014** · PHASE3 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 603 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Nilotinib
- **DRUG:** Ceritinib
- **DRUG:** Capmatinib
- **DRUG:** Lapatinib
- **DRUG:** Trametinib
- **COMBINATION_PRODUCT:** Trametinib and Dabrafenib
- **COMBINATION_PRODUCT:** Olaparib and Durvalumab
- **DRUG:** Palbociclib
- **DRUG:** Glasdegib
- **DRUG:** TAS-120
- **OTHER:** Next Generation sequencing exome

## Key facts

- **NCT ID:** NCT03784014
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-19
- **Primary completion:** 2023-12-01
- **Final completion:** 2026-01-20
- **Target enrollment:** 603 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03784014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03784014, "Molecular Profiling of Advanced Soft-tissue Sarcomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03784014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*